CoChat

Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseases

Youdim, M. B. H., Fridkin, M., Zheng, H. · 2004 · Journal of Neural Transmission

The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.

Abstract

Iron has been shown to accumulates at site where neurons degenerate in neurodegenerative diseases of Parkinson's disease, Alzheimer's disease, Huntington disease, amyotrophic lateral sclerosis and Friedreich ataxia. Iron is thought to participate or initiate oxidative stress via generation of reactive oxygen species (ROS), such as hydroxyl radical. Iron chelators are neuroprotective and prevent 6-hydroxydoapmine and MPTP dopaminergic neurotoxicity in rats and mice. However, their action on monoamine oxidase (MAO) A and B have not been determined previously since MAO-B inhibitors have been shown to be neuroprotective in cellular and animal models of Parkinson's disease. The chelators 8-hydroxyquinoline, O-phenanthroline, 2,2'-dipyridyl, U74500A and U74600F showed a preference for inhibition of rat brain mitochondrial MAO-A over MAO-B. Their IC(50) ranged from 10(-3) M to 10(-6) M, with 21-amino steroids (U74500A and U74006F) showing a greater selectivity and potency for MAO-A. Desferrioxamine (desferal), a prototype potent iron chelator, exhibited relatively poor MAO inhibitory. The inhibitions of MAO-A and B by 21-amino steroids (Lazaroids) were time dependent and irreversible. Those initiated by 8-hydroxyquinoline, 2,2'-dipyridyl and O-phenanthroline were fully reversible by enzyme dilution experiments. Both Fe(2+) and Fe(3+) reverse the MAO-A and B inhibition induced by the latter chelators, but not those initiated by 21-amino steroids. The data infer that either the inhibition of MAO by 21-amino steroids is either the resultant of their conversion to an irreversible covalently bound ligand or that the iron chelation moiety and MAO inhibitory activity in these compounds are not mutually shared. The results suggest that bifunctional brain penetrable drugs with iron chelating property and MAO inhibitory activity in could be the most feasible approach for neuroprotection in neurodegenerative diseases. Such drug would prevent participation of elevated iron in oxidative stress and formation of reactive hydroxyl radical, via its interaction with H(2)O2 (Fenton chemistry), generated as a consequence MAO and other oxidative enzyme reactions to generative cytotoxic reactive hydroxyl radical. We have now developed several of these compounds with neuroprotective, MAO inhibitory and iron chelating properties from our prototype iron chelators, VK-28 possessing propargylamine moiety of our anti-parkinson drug, rasagiline.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00702-004-0143-x

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 68 references

Cited by

See all 123

Metadata

Authors
Youdim, M. B. H., Fridkin, M., & Zheng, H.
Affiliations
  • Technion – Israel Institute of Technology (IL)
  • Weizmann Institute of Science (IL)
Venue
Journal of Neural Transmission
Published
2004-04-20
Volume
111
Issue
10-11
Pages
1455-1471
ISSN
  • 0300-9564 (ISSN-L)
  • 1435-1463
OpenAlex
W1967321583
Cited by
123
References
69
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 10 · 2012: 3
FWCI
4.47
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Neural Transmission (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
Parkinson's disease, iron chelation, monoamine oxidase inhibition, monoamine oxidase A, monoamine oxidase B, neuroprotection, neurodegenerative diseases, oxidative stress, hydroxyl radicals, lazaroids, deferoxamine, 8-hydroxyquinoline, 2,2'-bipyridine, 1,10-phenanthroline, iron accumulation, reactive oxygen species
MeSH terms
Animals, Brain, Indans, Iron Chelating Agents, Male, Mitochondria, Monoamine Oxidase, Monoamine Oxidase Inhibitors, Pargyline, Parkinson Disease, Piperazines, Propylamines, Quinolines, Drug Delivery Systems, Rats, Sprague-Dawley, Neuroprotective Agents, Neurodegenerative Diseases, Rats, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseases. https://app.cochat.ai/papers/10.1007/s00702-004-0143-x
The paper
Youdim, M. B. H., Fridkin, M., & Zheng, H. (2004). Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseases. Journal of Neural Transmission. https://doi.org/10.1007/s00702-004-0143-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.